Septic arthritis: A 12 years retrospective study in a rheumatological university clinic;Artriti settiche: Studio retrospettivo di 12 anni in un unico centro reumatologico

Reumatismo

Volumn 60, Issue 4, 2008, Pages 260-267

  Favero, Marta ^a   Schiavon, F ^a   Riato, L ^a   Carraro, V ^a   Punzi, L ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Articular pathology; Immunosuppressive drugs; Septic arthritis; Synovial fluid leukocyte count

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTHROCENTESIS; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC PATIENT; DISABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; JOINT CAVITY; JOINT PROSTHESIS; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; OUTPATIENT DEPARTMENT; PROSTHESIS INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; SYNOVIAL FLUID;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, INFECTIOUS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATOLOGY; TIME FACTORS; YOUNG ADULT;

EID: 65449139867     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Klein RS. Joint infection, with consideration of underlying disease and sources of bacteriemia in hematogenous infection. Clin Geriatr Med 1988; 4: 375-94.
2. Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15: 527-44.
3. Hunter JA, Blyth TH. A risk-benefit assessment of intraarticular corticosteroids in rheumatic disorders. Drug Saf 1999; 21: 353-65.
4. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 1995; 38: 1819-25.
5. Morgan DS, Fisher D, Merianos A, Currie BJ. An 18 year clinical review of septic arthritis from tropical Australia. Epidemiol Infect 1996; 117: 423-8.
6. Smith JW, Chalupa P, Shabaz Hasan M. Infectious arthritis: clinical features, laboratory findings and treatment. Clin Microbiol Infect 2006; 12: 309-14.
7. Tarkowski A. Infection and musculoskeletal conditions: Infectious arthritis. Best Pract Res Clin Rheumatol 2006; 20: 1029-44.
8. Gupta MN, Sturrock RD, Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford) 2001; 40: 24-30.
9. Goldenberg DL. Septic arthritis. Lancet. 1998; 351: 197-202.
10. Klippel JH et al. Arthritis Foundation: Primer on the Rheumatic Diseases 12 th ed Atlanta, Ga: Arthritis Foundation; 2001.
11. Dubost JJ, Soubrier M, De Champs C, Ristori JM, Bussiére JL, Sauvezie B. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 2002; 61: 267-9.
12. Gillespie WJ, Nade S. Musculoskeletal infections. Melbourne: Blackwell Scientific Publications, 1987.
13. Bresnihan B, Cunnane G. Infection complications associated with the use of biological agents. Rheum Dis Clin North Am 2003; 29: 185-202.
14. Sia IG, Berbari EF, Karchmer AW. Prosthetic joint infections. Infect Dis Clin North Am 2005; 19: 885-914.
15. Saraux A, Taelman H, Blanche P, Batungwanayo J, Clerinx J, Kagame A, et al. HIV infection as a risk factor for septic arthritis. Br J Rheumatol 1997; 36: 333-7.
16. Swan A, Amer H, Dieppe P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey. Ann Rheum Dis 2002; 61: 493-8.
17. Gavet F, Tournadre A, Soubrier M, Ristori JM, Dubost JJ. Septic arthritis in patients aged 80 and older: a comparison with younger adults. J Am Geriatr Soc 2005; 53: 1210-3.
18. Schattner A, Vosti KL. Bacterial arthritis due to beta-haemolytic streptococci of serogroups A, B, C, F and G. Analysis of 23 cases and a review of the literature. Medicine (Baltimore) 1997; 77: 122-39.
19. Abdullah S, Young-Min SA, Hudson SJ, Kelly CA, Heycock CR, Hamilton JD. Gross synovial fluid analysis in the differential diagnosis of joint effusion. J Clin Pathol 2007; 60: 1144-7.
20. Dieppe P, Swam A. Automated counting of white blood cells in synovial fluid. Rheumatology (Oxford) 2004; 43: 1201.
21. Ropes MW, Bauer W. Synovial fluid changes in joint disease. Cambridge, Harvard University Press, 1953.
22. Krey PR, Bailen DA. Synovial fluid leukocytosis. A study of extremes. Am J Med 1979; 67: 436-42.
23. McCutchan HJ, Fisher RC. Synovial leukocytosis in infectious arthritis. Clin Orthop Relat Res 1990; (257): 226-30.
24. Press J, Peled N, Buskila D, Yagupsky P. Leukocyte count in the synovial fluid of children with culture-proven brucellar arthritis. Clin Rheumatol 2002; 21: 191-3.
25. Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297: 1478-88.
26. McGillicuddy DC, Shah KH, Friedberg RP, Nathanson LA, Edlow JA. How sensitive is the synovial fluid white blood cell count in diagnosing septic arthritis? Am J Emerg Med 2007; 25: 749-52.
27. Li SF, Cassidy C, Chang C, Gharib S, Torres J. Diagnostic utility of laboratory tests in septic arthritis. Emerg Med J 2007; 24: 75-7.
28. Della Valle CJ, Sporer SM, Jacobs JJ, Berger RA, Rosenberg AG, Paprosky WG. Preoperative testing for sepsis before revision total knee arthoplasty. J Arthroplasty 2007; 22: 90-3.
29. Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 1151-7.
30. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46: 1157-1160.
31. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy.
32. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP, et al. The changing use of disease-modifying antirheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44: 1394-8.
33. Rahman MM, Leong KP, Edwards CJ, Chng HH. Five and a half year study of 107 patients with septic arthritis in a general hospital in Singapore. APLAR Journal of Rheumatology 2003; 6: 10-5.
34. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
35. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
36. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
37. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33.
38. Desai BS, Furst DE. Problem encountered during antitumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-9.
39. Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T. Role of anti-tumor necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect 2006; 12: 1151-3.
40. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tubercolosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
41. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-92.
42. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
43. Nadarajah K, Pritchard C. Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. J Clin Rheumatol 2005; 11: 120-2.